Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH), today announced an agreement to sell 3,000,000 shares of its common stock. The offering is expected to consist of 1,000,000 shares to be offered by the Company and 2,000,000 shares to be offered by certain of its existing stockholders (the “Selling Stockholders”), pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on Form S-3 and a related registration statement on Form S-3MEF filed with the SEC pursuant to Rule 462(b) under the Securities Act of 1933. The Company intends to use a combination of net proceeds from this offering, together with cash on hand, to repay approximately $20 million of the outstanding principal balance under its senior secured credit facilities. The Company will not receive any proceeds from the sale of shares by the Selling Stockholders. Credit Suisse will act as underwriter for the offering.
A shelf registration statement (including a prospectus) relating to the offering of common stock was filed with the SEC on August 5, 2016 (and became effective on August 31, 2016) and a related registration statement was filed with the SEC on November 15, 2016 pursuant to Rule 462(b) under the Securities Act of 1933 (and became automatically effective upon filing). Before you invest, you should read the prospectus included in the registration statements and the documents incorporated by reference therein as well as the prospectus supplement related to this offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the offering may also be obtained by contacting Credit Suisse Securities (USA) LLC., Attn: Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling (800) 221-1037, or by emailing firstname.lastname@example.org.
The offering of these securities will be made only by means of a prospectus supplement and the accompanying prospectus.
This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer to buy the securities may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date of the shelf registration statements.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada.
This press release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the offering. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “should,” “could,” “predicts,” “targets,” “hopes” or, in each case, their negatives or other variations or comparable terminology. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future, including risks and uncertainties relating to the consummation of the proposed offering by the Company and Selling Stockholders and the risks identified, or incorporated by reference, in the prospectus supplement or accompanying prospectus.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161115006768/en/Business Wire
Last updated on: 15/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.